Skip to main content
Clinical Trials/RBR-35mp4q
RBR-35mp4q
Completed
未知

Study of the role of hydroxychloroquine in immunomodulation and control of hypercoagulability in patients diagnosed with Primary antiphospholipid syndrome

Hemocentro- Universidade Estadual de Campinas0 sitesStarted: January 31, 2020Last updated:

Overview

Phase
未知
Status
Completed
Sponsor
Hemocentro- Universidade Estadual de Campinas

Overview

Brief Summary

No summary available.

Study Design

Study Type
Intervention

Eligibility Criteria

Ages
17Y to 65Y (—)

Inclusion Criteria

  • Confirmed diagnosis of primary antiphospholipid syndrome with thrombosis; age between 17 and 65 years old

Exclusion Criteria

  • Diagnosis of active neoplasia; presence of other associated autoimmune diseases; gestational period; antiphospholipid syndrome with isolated obstetric complications

Investigators

Sponsor
Hemocentro- Universidade Estadual de Campinas

Similar Trials